Меню
Набор скоро начнётся NCT07358858

A Food Effect Study of QLS1410 in Healthy Chinese Adults

Фаза I С лечением Uncontrolled Hypertension

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: QLS1410.
Кому может быть актуально
Состояния в реестре: Uncontrolled Hypertension. Базовые параметры: 18 лет — 55 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Randomized, Open-label, Two-period, Crossover Food Effect Study of QLS1410 in Healthy Chinese Adults

Обзор

This study is aimed to evaluate the effect of food on pharmacokinetics of QLS1410 in healthy Chinese adults.

Подробное описание

All the qualified participants will be randomized (1:1) to two treatment sequences (fed/fasting and fasting/fed). In each period, participants will receive a single dosing of QLS1410 tablets either with or without a high-fat breakfast. There will be a one-week washout period in this study.

Вмешательства

  • Препарат QLS1410
    QLS1410 tablets

Первичные конечные точки

  • AUC0-∞ [Срок оценки: 0 to 96 hours]
  • Area under the curve plasma concentration from time zero to Time of Last Quantifiable Concentration [Срок оценки: 0 to 96 hours]
  • Maximum observed plasma concentration [Срок оценки: 0 to 96 hours]

Критерии участия

Критерии включения

  • Able to understand and willing to comply with all study visits, procedures, restrictions and provide the written informed consent form (ICF).
  • Males and females aged 18 to 55 years, inclusive.
  • Weight ≥ 50 kg for males and ≥ 45 kg for females, Body mass index (BMI) between 18 and 26 kg/m\^2, inclusive, at screening.
  • Has a mean seated office systolic blood pressure (SBP) 110\~139 mmHg (inclusive) and diastolic blood pressure (DBP) 70\~89 mmHg (inclusive) at screening and baseline; measured 3 times consecutively (1-2 min intervals).
  • QTcF (QT corrected using Fridericia's formula) <450 ms for males and <470 ms for females.
  • Participants (including partners) must agree to abstain from sperm/egg donation and pregnancy plans, and to use highly effective contraception, from signing the ICF until 3 months after receiving the last dose of investigational product.

Критерии исключения

  • Any medical condition/disease at screening deemed by the investigator to require exclusion, including but not limited to the cardiovascular, respiratory, digestive, urinary, endocrine metabolic, skeletal, muscular, hematologic, immune, nervous system.
  • Dysphagia or any surgical condition/disease that may affect drug absorption, distribution, metabolism, or excretion, at screening.
  • Use of systemic corticosteroids within 3 months prior to screening.
  • Any clinically significant abnormal result of vital signs, physical examinations, laboratory tests, chest X-ray, and abdominal B-ultrasound, at screening.
  • Active viral hepatitis (B or C), TP, and HIV as demonstrated by positive serology at Screening.
  • Mean pulse >100 or <50 bpm after ≥5 min of rest at screening (measured 3 times consecutively).
  • Any of the following laboratory abnormalities at screening: ALT or AST >1.5 x upper limit of normal (ULN); Total bilirubin >1.5 x ULN (participants with Gilbert's syndrome may qualify if direct bilirubin ≤ULN); Creatinine >ULN or eGFR <90 mL/min/1.73 m²; Serum potassium >ULN or sodium <135 mmol/L.
  • Smoking >5 cigarettes/day on average within 6 months before screening, or current use of e-cigarettes.
  • Alcohol consumption >14 units/week (1 unit = 357 mL of 3.5% beer, 27 mL of 40% spirits, or 104 mL of 12% wine) within 6 months before screening, or has a positive breath alcohol test at screening.
  • Blood donation >400 mL within 3 months or >200 mL within 4 weeks before screening, or plan to donate blood during the study.
  • Use of strong CYP3A4 or CYP1A2 inhibitors within 7 days or 5 half-lives (whichever is longer) before screening. Use of strong CYP3A4 inducer within 14 days or 5 half-lives (whichever is longer) before screening.
  • Use of any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks or 5 half-lives (whichever is longer) prior to randomization.
  • Pregnant/lactating females or positive pregnancy test at screening.
  • Inability to tolerate a high-fat meal.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07358858 · QSL1410-102

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗